Matrifen® for Therapy of Severe Chronic Pain®
Efficacy of Matrifen® in Patients Older Than 18 Years With Severe, Chronic Pain Including Quality of Life Questionnaire
Sponsor: Nycomed
Listed as NCT00699335, this observational or N/A phase trial focuses on Severe Chronic Pain and remains completed. Sponsored by Nycomed, it has been updated 9 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Completed
-
Oct 2025 — Nov 2025 [monthly]
Completed
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
▶ Show 4 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nycomed
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalen, Germany , Abensberg, Germany , Adelebsen, Germany , Ahaus, Germany , Ahlen, Germany , Ahrensburg, Germany , Albstadt, Germany , Aldenhoven, Germany , Alfeld, Germany , Alfhausen, Germany and 878 more locations